NBT Bank N.A. Makes New $1.16 Million Investment in Stryker Corporation $SYK

NBT Bank N.A. purchased a new position in Stryker Corporation (NYSE:SYK) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 4,215 shares of the medical technology company’s stock, valued at approximately $1,161,000.

A number of other hedge funds have also made changes to their positions in SYK. State Street Corp grew its holdings in shares of Stryker by 1.2% during the second quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock worth $4,903,772,000 after buying an additional 183,400 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after acquiring an additional 45,478 shares during the period. Bank of America Corp DE acquired a new stake in shares of Stryker in the second quarter worth approximately $1,404,284,000. Royal Bank of Canada boosted its position in shares of Stryker by 6.5% in the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after acquiring an additional 199,863 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Stryker by 21.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock valued at $846,723,000 after purchasing an additional 481,175 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE SYK opened at $307.65 on Friday. Stryker Corporation has a twelve month low of $267.00 and a twelve month high of $389.33. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $118.01 billion, a price-to-earnings ratio of 31.88, a price-to-earnings-growth ratio of 1.98 and a beta of 0.78. The business has a 50 day simple moving average of $295.23 and a 200-day simple moving average of $311.93.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts expect that Stryker Corporation will post 14.93 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is 36.48%.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent research reports. Raymond James Financial set a $370.00 target price on shares of Stryker in a report on Friday, July 31st. Truist Financial lowered their price target on Stryker from $340.00 to $310.00 and set a “hold” rating for the company in a report on Tuesday, October 6th. JPMorgan Chase & Co. cut their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Wolfe Research downgraded Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Finally, Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $369.00.

Insiders Place Their Bets

In other Stryker news, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the sale, the director directly owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 351,267 shares of company stock worth $118,197,701 over the last ninety days. Company insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.